320
Participants
Start Date
August 13, 2020
Primary Completion Date
February 25, 2025
Study Completion Date
May 1, 2025
TST001
TST001 will be administered by specified doses on specified day
Oxaliplatin
Oxaliplatin will be administered by specified doses on specified day
Capecitabine
Capecitabine will be administered by specified doses on specified day
Paclitaxel
Paclitaxel will be administered by specified doses on specified day
Gemcitabine
Gemcitabine will be administered by specified doses on specified day
Cisplatin
Cisplatin will be administered by specified doses on specified days Oxaliplatin will be administered by specified doses on specified day Drug: Capecitabine Capecitabine will be administered by specified doses on specified day
Nivolumab
Nivolumab will be administered by specified doses on specified day
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
The First Affiliated Hospital of Bengbu Medical College, Bengbu
RECRUITING
Beijing Friendship Hospital, Capital Medical University, Beijing
NOT_YET_RECRUITING
Peking Union Medical College Hospital, Beijing
NOT_YET_RECRUITING
Peking University International Hospital, Beijing
RECRUITING
The First Affiliated Hospital of Chongqing Medical University, Chongqing
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Fujian Medical University Union Hospital, Fuzhou
RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
RECRUITING
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou
NOT_YET_RECRUITING
The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi
RECRUITING
Hainan Provincial People's Hospital, Haikou
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
RECRUITING
Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Zhongnan Hospital of Wuhan University, Wuhan
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Xiangya Hospital, Central South University, Changsha
RECRUITING
Suzhou Municipal Hospital, Suzhou
RECRUITING
The Second Affiliated Hospital of Soochow University, Suzhou
RECRUITING
Xuzhou Central Hospital, Xuzhou
RECRUITING
The Second Affiliated Hospital of Nanchang University, Nanchang
RECRUITING
Jilin Cancer Hospital, Changchun
RECRUITING
The First Hospital of Jilin University, Changchun
RECRUITING
The First Affiliated Hospital of Jinzhou Medical University, Jinzhou
RECRUITING
Liaoning Cancer Hospital & Institute, Shenyang
RECRUITING
The First Hospital of China Medical University, Shenyang
RECRUITING
Jinan Central Hospital, Jinan
RECRUITING
Linyi Cancer Hospital, Linyi
RECRUITING
The Affiliated Hospital of Qingdao University, Qingdao
RECRUITING
Fudan University Shanghai Cance Center, Shanghai
RECRUITING
Zhongshan Hospital Fudan University, Shanghai
RECRUITING
Sichuan Cancer Hospital, Chengdu
RECRUITING
West China Hospital, Sichuan University, Chengdu
RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjin
RECRUITING
Tianjin Medical University General Hospital, Tianjin
RECRUITING
First Affiliated Hospital of Zhejiang University, Hangzhou
RECRUITING
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Suzhou Transcenta Therapeutics Co., Ltd.
INDUSTRY